Vir Biotechnology, Inc. (VIR)
Healthcare • Biotechnology
StockNasdaqGSUnited StatesUS92764N1028
Kyvero is an independent information site. It is not affiliated with, endorsed by or sponsored by Vir Biotechnology, Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price history
Daily prices in USD. Dividends, results and news are marked on the day they happened; click a day to see them.
Updated 12 Nov 2026 20:55. Information, not advice. Showing the last 12 months. Create a free account to see the whole history
Results
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 24 Feb 2027 16:00 | -0.24 | — | — | Upcoming |
| 04 Nov 2026 16:00 | -0.75 | -0.57 | +23.5% | Beat |
| 05 Aug 2026 16:00 | 0.90 | 0.47 | -47.5% | Miss |
| 06 May 2026 16:00 | 0.48 | -0.85 | -276.6% | Miss |
| 23 Feb 2026 17:00 | -0.45 | -0.31 | +31.6% | Beat |
| 05 Nov 2025 16:00 | -0.86 | -1.17 | -36.0% | Miss |
| 06 Aug 2025 16:00 | -0.72 | -0.80 | -11.4% | Miss |
| 07 May 2025 16:00 | -0.84 | -0.88 | -4.4% | Miss |
| 26 Feb 2025 16:00 | -0.87 | -0.76 | +12.7% | Beat |
| 31 Oct 2024 16:00 | -1.08 | -1.56 | -44.0% | Miss |
| 01 Aug 2024 16:00 | -0.89 | -1.02 | -14.1% | Miss |
| 02 May 2024 16:00 | -1.05 | -0.48 | +54.3% | Beat |
| 22 Feb 2024 16:00 | -1.00 | -0.86 | +14.0% | Beat |
| 02 Nov 2023 16:00 | -1.19 | -1.22 | -2.8% | Miss |
| 03 Aug 2023 16:00 | -1.19 | -1.45 | -21.9% | Miss |
| 04 May 2023 16:00 | -0.86 | -1.06 | -23.0% | Miss |
| 23 Feb 2023 16:00 | -0.42 | -0.76 | -82.5% | Miss |
| 03 Nov 2022 16:00 | -0.31 | 1.30 | +514.5% | Beat |
| 09 Aug 2022 16:00 | 0.46 | -0.58 | -227.4% | Miss |
| 05 May 2022 16:00 | 3.62 | 3.85 | +6.5% | Beat |
| 24 Feb 2022 16:00 | 1.56 | 3.92 | +151.2% | Beat |
| 04 Nov 2021 16:00 | 0.09 | 0.82 | +855.3% | Beat |
| 05 Aug 2021 16:00 | -0.40 | 0.46 | +215.6% | Beat |
| 06 May 2021 16:00 | -0.11 | -1.32 | -1,137.9% | Miss |
| 25 Feb 2021 16:00 | -0.70 | -0.83 | -18.9% | Miss |
| 10 Nov 2020 16:00 | -0.60 | -0.67 | -12.0% | Miss |
| 11 Aug 2020 16:00 | -0.62 | -0.27 | +56.2% | Beat |
| 12 May 2020 16:00 | -0.56 | -0.71 | -27.5% | Miss |
| 26 Mar 2020 16:00 | -0.63 | -0.69 | -10.1% | Miss |
| 19 Nov 2019 16:00 | -3.33 | -4.60 | -37.9% | Miss |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 66.5M | +4.4% | -438M | -658.4% | -3.16 | +17.5% | -396.6M |
| 2024 | 63.7M | +61.3% | -522M | -819.2% | -3.83 | +16.6% | -453.7M |
| 2023 | 39.5M | -97.5% | -615.1M | -1,557.4% | -4.59 | -219.8% | -800.4M |
| 2022 | 1.6B | — | 515.8M | 32.6% | 3.83 | — | 1.6B |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| 12 Nov 2026 | 12.90 | 12.96 | 12.02 | 12.13 | -7.62% | 1,338,333 | |
| 11 Nov 2026 | 13.22 | 13.43 | 12.94 | 13.13 | -0.15% | 1,292,200 | |
| 10 Nov 2026 | 13.66 | 13.74 | 13.11 | 13.15 | -3.63% | 1,299,700 | |
| 09 Nov 2026 | 13.15 | 14.38 | 13.00 | 13.65 | +11.75% | 7,122,500 | |
| 06 Nov 2026 | 11.30 | 12.45 | 11.30 | 12.21 | +10.80% | 1,895,300 | |
| 05 Nov 2026 | 11.92 | 12.16 | 10.98 | 11.02 | -6.37% | 2,932,600 | |
| 04 Nov 2026 | 11.68 | 11.81 | 11.17 | 11.77 | +4.90% | 2,804,700 | |
| 03 Nov 2026 | 11.10 | 11.38 | 11.10 | 11.22 | +2.00% | 1,553,200 | |
| 02 Nov 2026 | 11.36 | 11.55 | 11.00 | 11.00 | -2.65% | 1,377,500 | |
| 30 Oct 2026 | 11.63 | 11.84 | 11.18 | 11.30 | -3.83% | 1,267,300 | |
| 1,245 older periods: create a free account to see the whole history | |||||||
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- Vir Biotechnology Hepatitis Delta Treatment Meets Phase III Goals, With 79% Virus-Free at Week 48 (opens in a new tab) MarketBeat · 10 Nov 2026 14:12
- Morgan Stanley Maintains Overweight on Vir Biotechnology, Raises Price Target to $28 (opens in a new tab) Benzinga · 10 Nov 2026 13:26
- Vir Biotechnology’s hepatitis D drug scores in Phase II and Phase III trials (opens in a new tab) Clinical Trials Arena · 10 Nov 2026 10:17
- Evercore ISI Group Maintains Outperform on Vir Biotechnology, Raises Price Target to $25 (opens in a new tab) Benzinga · 10 Nov 2026 10:15
- Vir Biotechnology, Inc. (VIR) Discusses ECLIPSE 1 Topline Results and Expanded SOLSTICE Data - Slideshow (opens in a new tab) SeekingAlpha · 10 Nov 2026 08:34
- Vir Biotechnology: Fairly Valued After Phase 3 Success? (opens in a new tab) SeekingAlpha · 10 Nov 2026 08:15
- Is Vir Biotechnology (VIR) A Bargain After Its Hepatitis Delta Phase 3 Win? (opens in a new tab) Simply Wall St. · 10 Nov 2026 03:12
- Is Vir Biotechnology (VIR) Overvalued After Its 127% Run? (opens in a new tab) Simply Wall St. · 09 Nov 2026 20:07
- Vir Biotechnology (VIR) Says Its Hepatitis Delta Therapy Met All Phase 3 Endpoints (opens in a new tab) Simply Wall St. · 09 Nov 2026 19:13
- Vir hepatitis D drug succeeds in first pivotal study (opens in a new tab) BioPharma Dive · 09 Nov 2026 17:09
- Vir Biotechnology, Inc. (VIR) Discusses ECLIPSE 1 Topline Results and Expanded SOLSTICE Data Transcript (opens in a new tab) SeekingAlpha · 09 Nov 2026 14:10
- Vir Biotechnology Shares Rise 22% as Phase 3 Hepatitis Delta Trial Meets Primary and Secondary Endpoints (opens in a new tab) InvestorsHub · 09 Nov 2026 13:56
- Wall Street Analysts Predict a 75.59% Upside in Vir Biotechnology (VIR): Here's What You Should Know (opens in a new tab) Zacks · 09 Nov 2026 13:55
- Vir Stock Soars After Late-Stage Trial Win. Why Biotech Could Be Headed for the FDA (opens in a new tab) GuruFocus.com · 09 Nov 2026 13:45
- Vir Biotechnology stock jumps 22% after hepatitis delta Phase 3 trial success (opens in a new tab) Investing.com · 09 Nov 2026 13:06
Headlines link to the original articles of the publishers shown; Kyvero does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 13.13 USD
- Market cap
- 2.2B
- Exchange
- NasdaqGS
- Country
- United States
- Sector
- Healthcare
- Industry
- Biotechnology
- Currency
- USD
Dividends
No dividends on record.
Why this score
Similar shares
Follow VIR and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.